Paul Austin advocates for increased government funding of psychedelic therapy research, which can transform the way we understand and treat mental health conditions.
Anne McGuire and Michael Orsini offer a critical analysis of how the business of selling health is influenced by popular images of illness and disability that circulate in the places and spaces where care should be the primary concern.
Françoise Baylis continues to advocate for broad societal consensus on the future of germline genome editing and sees the Parliamentary Assembly of the Council of Europe as an ally given their support of broad public engagement.
Mary Jean Hande and Christine Kelly advocate for a publicly funded home care service that is guided by the best practices and the experiences of the people on the frontlines of care, namely health care workers, patients, and their families.
Erika Dyck describes how the recent surge in psychedelic research presents opportunities to rethink how we do science, and how we measure the impact of science.